Biodexa announces enrolment of first patients into pivotal phase 3 serenta trial in familial adenomatous polyposis (fap)

August 18, 2025 biodexa announces enrolment of first patients into pivotal phase 3 serenta trial in familial adenomatous polyposis (fap) opportunity to be first mover in $7.3bn addressable market biodexa pharmaceuticals plc (“biodexa” or “the company”), (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the enrolment of the first two patients by the pan american center for oncology trials in san juan, puerto rico into its pivotal phase 3 serenta trial of erapa in patients with familial adenomatous polyposis (fap), a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer. the only current treatment option is sequential resection of the gastrointestinal tract.
BDRX Ratings Summary
BDRX Quant Ranking